Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation

Inhibitors blocking the PD-1/PD-L1 immune checkpoint demonstrate impressive anti-tumor immunity, and small molecule inhibitors disclosed by the Bristol-Myers Squibb (BMS) company have become a hot topic. In this work, by modifying the carbonyl group of BMS-202 into a hydroxyl group to achieve two en...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jianhuai, Wang, Bingfeng, Yang, Yang, Liu, Boping, Jin, Yulong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866166/
https://www.ncbi.nlm.nih.gov/pubmed/36674800
http://dx.doi.org/10.3390/ijms24021280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866166/
https://www.ncbi.nlm.nih.gov/pubmed/36674800
http://dx.doi.org/10.3390/ijms24021280

Ejemplares similares